RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has maintained an 'Outperform' rating on Edgewise Therapeutics and increased the price target from $32 to $42.
September 20, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has increased the price target for Edgewise Therapeutics from $32 to $42 while maintaining an 'Outperform' rating, indicating positive expectations for the stock.
The increase in price target from $32 to $42 by RBC Capital suggests a positive outlook for Edgewise Therapeutics. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100